MHC Class I Overexpression on Muscles in Early Juvenile Dermatomyositis

Journal of Rheumatology

Volumn 31, Issue 3, 2004, Pages 605-609

  Li, Charles K C ^a,b   Varsani, Hemlata ^a,b   Holton, Janice L ^a,d   Gao, Bin ^a,b   Woo, Patricia ^a,b   Wedderburn, Lucy R ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Paediatric Rheumatology ^*

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Immunohistochemistry; Inflammatory myopathy; Juvenile dermatomyositis; MHC Class I

Indexed keywords

CD56 ANTIGEN; CELL ADHESION MOLECULE; DYSTROPHIN; IMMUNOGLOBULIN HEAVY CHAIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MICROSCOPY; MONONUCLEAR CELL; MUSCLE BIOPSY; MUSCLE INJURY; NATURAL KILLER CELL; PRIORITY JOURNAL; STEROID THERAPY;

ADOLESCENT; BIOPSY; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; GENE EXPRESSION; GENES, MHC CLASS I; HUMANS; MUSCLE, SKELETAL;

EID: 1542515175     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
2. Pachman LM. Juvenile dermatomyositis: immunogenetics, pathophysiology, and disease expression. Rheum Dis Clin North Am 2002;28:579-602.
3. Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998;25:1198-204.
4. Ramanan AV, Feldman BM. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 2002;14:658-62.
5. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988;23:64-72.
6. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989;20:224-31.
7. McDouall RM, Dunn MJ, Dubowitz V. Expression of class I and II MHC antigens in neuromuscular diseases. J Neurol Sci 1989;89:213-26.
8. Rowe D, Isenberg DA, Beverley PC. Monoclonal antibodies to human leucocyte antigens in polymyositis and muscular dystrophy. Clin Exp Immunol 1983;54:327-36.
9. McDouall RM, Dunn MJ, Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci 1990;99:199:217.
10. Topaloglu H, Muntoni F, Dubowitz V, Sewry C. Expression of HLA class I antigens in skeletal muscle is diagnostic marker in juvenile dermatomyositis. J Child Neurol 1997;12:60-3.
11. Illa I, Leon-Monzon M, Dalakas MC. Regenerating and denervated human muscle fibers and satellite cells express neural cell adhesion molecule recognized by monoclonal antibodies to natural killer cells. Ann Neurol 1992;31:46-52.
12. Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999;42:2213-9.
13. Sallum AM, Kiss MH, Sachetti S, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr 2002;60:889-99.
14. Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol 1991;146:4421-6.
15. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984;38:287-92.
16. Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 2000;97:9209-14.
17. Englund P, Lindroos E, Nennesmo I, Klareskog L, Lundberg IE. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001;159:1263-73.
18. Lundberg IE. The physiology of inflammatory myopathies: an overview. Acta Physiol Scand 2001;171:207-13.
19. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208.
20. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 1986;19:112-25.
21. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986;17:704-21.
22. Orimo S, Koga R, Goto K, et al. Immunohistochemical analysis of perforin and granzyme A in inflammatory myopathies. Neuromuscul Disord 1994;4:219-26.
23. Pachman LM, O'Gorman MRG, Lawton T, et al. Studies of muscle biopsies (MBx) from DQA*0501+ untreated children with juvenile dermatomyositis (JDM) very early in their disease course: evidence of a TCRb8 motif and increase CD56+ NK cells [abstract]. Arthritis Rheum 1998;41 Suppl 9:203.